Bronchiectasis Respiratory Bronchiectasis
Conditions
Interventions
Tests will look at the lungs to see how they are affected by bronchiectasis. These tests will include a CT scan, lung function tests and a bronchoscopy with lung biopsies. The researchers wish to stud
Sponsors
University of Dundee
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Bronchiectasis cohort: 1. Age >18 years 2. Bronchiectasis diagnosed by CT scan 3. Symptoms consistent with bronchiectasis: cough, sputum and/or frequent respiratory tract infections 4. Clinically stable defined by the absence of antibiotic therapy in the previous 4 weeks Healthy control cohort: 1. Age >18 years
Exclusion criteria
Exclusion criteria: Bronchiectasis cohort: 1. A primary diagnosis of asthma or COPD (secondary diagnoses and individuals with historical misdiagnosis will be permitted) 2. Immunodeficiency requiring immunoglobulin replacement therapy 3. Active allergic bronchopulmonary aspergillosis (defined by receipt of oral corticosteroids or anti-fungal therapy) 4. Active tuberculosis 5. Traction bronchiectasis due to interstitial lung disease 6. Active SARS-CoV-2 infection or contact with a confirmed case in the previous 14 days 7. Active malignancy excluding non-melanoma skin cancer 8. Antibiotic treatment for an acute respiratory tract infection or exacerbation in the previous 4 weeks 9. Treatment with anticoagulants 10. Any contraindication to study procedures including bronchoscopy 11. Current smoking or smoking in the preceding 3 months Healthy control cohort: 1. Any respiratory diagnosis (asthma, COPD, bronchiectasis, pulmonary fibrosis or any other chronic respiratory condition requiring regular treatment) 2. Inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease, and any other connective tissue disease 3. Active SARS-CoV-2 infection or contact with a confirmed case in the previous 14 days 4. Active malignancy excluding non-melanoma skin cancer 5. Antibiotic treatment for an acute respiratory tract infection in the previous 4 weeks 6. Any contraindication to study procedures including bronchoscopy 7. Current smoking or smoking in the preceding 3 months 8. Upper respiratory tract infection in the previous 4 weeks or current sinusitis 9. Treatment with anticoagulants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The molecular endotypes of bronchiectasis during stable disease, determining by integrating data from multiple sources including clinical, inflammatory, microbiological, mucociliary and pathological assessments to identify candidate endotypes. Cross-sectional at baseline (single timepoint). | — |
Secondary
| Measure | Time frame |
|---|---|
| Biological characteristics measured at a single time point: 1.1. Inflammatory markers – including blood eosinophils, serum biomarkers 1.2. Microbiology – including BAL culture and sequencing 1.3. Lung physiology – including Spirometry and lung function testing | — |
Countries
Scotland, United Kingdom
Outcome results
None listed